Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 December 2006, Vol. 108, No. 13, pp. 4194-4197.
Prepublished online as a Blood First Edition Paper on August 31, 2006; DOI 10.1182/blood-2006-06-029355.

This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Table and Figures
Right arrow Erratum (v109,p2717)
Right arrow All Versions of this Article:
blood-2006-06-029355v1
108/13/4194    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moreaux, J.
Right arrow Articles by Klein, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moreaux, J.
Right arrow Articles by Klein, B.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted June 20, 2006
Accepted August 2, 2006

CD200 is a new prognostic factor in Multiple Myeloma

Jerome Moreaux, Dirk Hose, Thierry Reme, Eric Jourdan, Michael Hundemer, Eric Legouffe, Philippe Moine, Philippe Bourin, Marion Moos, Jill Corre, Thomas Mohler, John De Vos, Jean francois Rossi, Hartmut Goldschmidt, and Bernard Klein*

CHU Montpellier, Institute of Research in Biotherapy, Montpellier, France
Medizinische Klinik und Poliklinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany
CHU Nimes, Internal Medicine Department B, Nimes, France
CHU Montpellier, Department of Hematology and Clinical Oncology, Montpellier, France
Laboratoire de Therapie Cellulaire-Etablissement Francais du sang, Toulouse

* Corresponding author; email: klein{at}montp.inserm.fr.

Using Affymetrix microarrays, we identified the expression of the CD200 gene in multiple myeloma cells (MMC) of 112 patients with newly-diagnosed multiple myeloma (MM). The CD200 gene was either absent or present (Affymetrix call) in 22% and 78% of MMC, respectively. The CD200 gene is not expressed in cells of the patients' bone marrow (BM). CD200 is a membrane glycoprotein that imparts an immunoregulatory signal through CD200R, leading to the suppression of T-cell-mediated immune responses. Patients with CD200absent MMC have an increased event free survival (24 months) compared to patients with CD200present MMC (14 months), after high-dose therapy and stem cell transplantation. In a Cox-proportional-hazard model, the absence or presence of CD200 expression in MMC is predictive for EFS for patients independently of ISS stage or B2M serum levels. Thus, CD200 is an independent prognosis factor for patients with MM that could represent a new therapeutic target in MM.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

No tumor-CD200 expression, please!
Reginald Gorczynski
Blood 2006 108: 3958. [Full Text] [PDF]





click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020